Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer
Laurence Booth, Andrew Poklepovic, Paul Dent
Biochemical Pharmacology (2020) Vol. 178, pp. 114067-114067
Open Access | Times Cited: 22

Showing 22 citing articles:

Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives
Jiaxi Liu, Yongya Wu, Meng Sha, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 47
Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer
Dujuan Cao, Qianqian Song, Junqi Li, et al.
Expert Reviews in Molecular Medicine (2021) Vol. 23
Closed Access | Times Cited: 37
Oxidative Stress Activated by Sorafenib Alters the Temozolomide Sensitivity of Human Glioma Cells Through Autophagy and JAK2/STAT3-AIF Axis
Jianwei Wei, Zhengfeng Wang, Weiwei Wang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 27
Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer
Xuesong Xiang, Pengcheng Li, Wenquan Wang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 1, pp. 188676-188676
Closed Access | Times Cited: 18
Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma
Yamin Jie, Guijun Liu, E Mingyan, et al.
European Journal of Pharmacology (2021) Vol. 906, pp. 174214-174214
Closed Access | Times Cited: 23
Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib
Paul Dent, Laurence Booth, Andrew Poklepovic, et al.
Biochemical Pharmacology (2021) Vol. 190, pp. 114642-114642
Open Access | Times Cited: 19
Epigenetic control of pancreatic cancer metastasis
Lukas Krauß, Carolin Schneider, Elisabeth Heßmann, et al.
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 4, pp. 1113-1131
Open Access | Times Cited: 7
Pharmacological Targeting of Ferroptosis in Cancer Treatment
M A Khan, Trilochan Satapathy, Kalpana Sen, et al.
Journal of Drug Delivery and Therapeutics (2024) Vol. 14, Iss. 2, pp. 205-221
Open Access | Times Cited: 2
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma
Andrew S Poklepovic, Palak Shah, Mary Beth Tombes, et al.
(2024)
Closed Access | Times Cited: 2
GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells
Laurence Booth, Cameron West, Robert P. Moore, et al.
Oncotarget (2022) Vol. 13, Iss. 1, pp. 92-104
Open Access | Times Cited: 11
Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells
Laurence Booth, Jane L. Roberts, Andrew Poklepovic, et al.
Anti-Cancer Drugs (2023)
Closed Access | Times Cited: 6
Pharmacological Targeting of Ferroptosis in Cancer Treatment
Amaneh Mohammadi Roushandeh, Mehryar Habibi Roudkenar, Mehdi Rabiee Valashedi, et al.
Current Cancer Drug Targets (2021) Vol. 22, Iss. 2, pp. 108-125
Closed Access | Times Cited: 11
Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer
Duancheng Guo, Long‐Yun Ye, Weiding Wu, et al.
Acta Biochimica et Biophysica Sinica (2023) Vol. 55, Iss. 6, pp. 923-937
Open Access | Times Cited: 3
Identifying efficient controls of complex interaction networks using genetic algorithms
Victor Popescu, Krishna Kanhaiya, Iulian Năstac, et al.
arXiv (Cornell University) (2020)
Open Access | Times Cited: 4
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
Jane L. Roberts, Laurence Booth, Andrew Poklepovic, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 4
A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer
Yang Liu, Xiaowei Zhang, Ping Zhang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 10, pp. 4253-4272
Open Access | Times Cited: 1
Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells
Laurence Booth, Andrew Poklepovic, John F. Hancock, et al.
Anti-Cancer Drugs (2023) Vol. 34, Iss. 9, pp. 1025-1034
Closed Access | Times Cited: 1
Apoptosis
Laurence Booth, Andrew Poklepovic, Paul Dent
Elsevier eBooks (2024)
Closed Access
Multi‐kinase Inhibitors for the Treatment of Pancreatic Cancer
Paul Dent, Andrew Poklepovic
(2024), pp. 463-468
Closed Access
The development of multi-kinase inhibitors as pancreatic cancer therapeutics
Paul Dent, Andrew Poklepovic, Laurence Booth, et al.
Anti-Cancer Drugs (2021) Vol. 32, Iss. 8, pp. 779-785
Closed Access | Times Cited: 3
Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours
Paul Dent, Laurence Booth, Andrew Poklepovic, et al.
European Medical Journal (2022), pp. 127-133
Open Access | Times Cited: 1
Network controllability solutions for computational drug repurposing using genetic algorithms
Victor Popescu, Krishna Kanhaiya, Iulian Năstac, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 1
Page 1

Scroll to top